Conference Cochairs:
Lisa M. Coussens, OHSU Knight Cancer Institute, Portland, Oregon
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

[R] Remote Presentation
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

THURSDAY, SEPTEMBER 8
Welcome and Opening Lecture [CME Eligible]
Liberty Ballroom CD
6:45 p.m.-7:30 p.m.

  6:45-7:00 p.m. Welcome from Cochairs
  Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

  7:00-7:30 p.m. Opening Presentation
  Angela M. Belcher, Massachusetts Institute of Technology, Cambridge, Massachusetts

Opening Reception
Liberty Ballroom AB
7:30 p.m.-10:00 p.m.

FRIDAY, SEPTEMBER 9
7:00 a.m.–8:00 a.m. Breakfast
Liberty Ballroom AB

8:00 a.m.–10:00 a.m. Plenary Session 1: Pathology [CME Eligible]
Liberty Ballroom CD
Session Chair: Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

  8:00 a.m.-8:30 a.m. DCIS: Pathological heterogeneity and prognosis definition [R]
  Anne Vincent-Salomon, Institut Curie, Paris, France
8:30 a.m.-9:00 a.m.  Preinvasive breast lesions: an integrated pathology and genomics perspective  
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

9:00 a.m.-9:30 a.m.  How to solve the uncomfortable truth of DCIS?  
Jelle Wesseling, Netherlands Cancer Institute, Amsterdam, The Netherlands

9:30 a.m.-9:45 a.m.  Lightning talks from submitted abstracts  
Spatial proximity between CD8 + T cells and tumor cells correlates with invasive recurrence in DCIS*  
Michael Campbell, University of California, San Francisco, San Francisco, California

Genomic predictor can discriminate between high- and low-risk DCIS*  
Elinor J. Sawyer, King’s College London, London, United Kingdom

Pioneering genetic rat models of Ductal Carcinoma in situ (DCIS)*  
Catrin Lutz, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands

9:45 a.m.-10:00 a.m.  Discussion

10:00 a.m.–10:30 a.m.  Break  
Liberty Ballroom Foyer

10:30 a.m.–12:20 p.m.  Plenary Session 2: Artificial Intelligence [CME Eligible]  
Session Chair: Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

10:30 a.m.-11:00 a.m.  Artificial intelligence for breast pathology: Challenges and opportunities (and more challenges!)  
Michael G. Drage, PathAI, Inc., Boston, Massachusetts

11:00 a.m.-11:30 a.m.  Co-evolving artificial intelligence and pathology  
Yinyin Yuan, Institute of Cancer Research, London, United Kingdom

*Lightning Talk selected from proffered abstracts
11:30 a.m.-11:35 a.m.  Lightning talks from submitted abstracts
Radiogenomics for predicting underestimation of invasiveness in ductal carcinoma in situ (DCIS) diagnosed with vacuum assisted breast biopsy: study rationale and design*
Matteo Lazzeroni, European Institute of Oncology IRCCS, Milan, Italy

11:35 a.m.-12:05 p.m.  Breast pathology and AI: Are we there yet? [R]
Matthew G. Hanna, Memorial Sloan Kettering Cancer Center, New York, New York

12:05 p.m.-12:20 p.m.  Discussion

12:20 p.m.–2:00 p.m.  Poster Session A/ Lunch (provided)
Liberty Ballroom AB

2:15 p.m.–4:45 p.m.  Plenary Session 3: Model Systems [CME Eligible]
Liberty Ballroom CD
Session Chair: Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

2:15 p.m.-2:45 p.m.  Mouse-INtraDuctal (MIND): An in vivo model for the discovery of epithelial/stromal cross talks that drive DCIS invasive and metastatic progression
Fariba Behbod, University of Kansas Medical Center, Kansas City, Kansas

2:45 p.m.-3:15 p.m.  Title to be announced
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, Massachusetts

3:15 p.m.-3:30 p.m.  Lightning talks from submitted abstracts
Intraductal administration of a recombinant transferrin receptor-directed immunotoxin clears ductal carcinoma in situ in preclinical mammary in-duct (MIND) models of breast cancer*
Saraswati Sukumar, Johns Hopkins University School of Medicine, Baltimore, Maryland

*Lightning Talk selected from proffered abstracts
A living biobank of patient-derived ductal carcinoma in situ (DCIS) Mouse-INtraDuctal (MIND) xenografts identifies multiple risk factors of invasive progression*
Stefan Hutten, Netherlands Cancer Institute, Amsterdam, The Netherlands

Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC*
Sasha Stanton, Earle A. Chiles Research Institute, Portland, Oregon

3:30 p.m.-4:00 p.m. Patient-derived and genetically engineered models of Ductal Carcinoma in Situ
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

4:00 p.m.-4:30 p.m. Patient-derived organoids as models for breast cancer prevention and interception
Jennifer Rosenbluth, University of California, San Francisco, San Francisco, California

4:30 p.m.-4:45 p.m. Discussion

4:45 p.m.-5:15 p.m. Break
Liberty Ballroom Foyer

5:15 p.m.-7:35 p.m. Open Satellite Session: Updates from the Human Tumor Atlas Network and PRECISION Consortia [Not CME Eligible]
Liberty Ballroom CD
Chairs: Robert West, Stanford University, Stanford, California and Jelle Wesseling, Netherlands Cancer Institute, Amsterdam, The Netherlands

5:15 p.m.-5:45 p.m. Session 1: Spatial Genomics
Moderators: Robert West, Stanford University, Stanford, California and Esther H. Lips
Netherlands Cancer Institute, Amsterdam, The Netherlands

5:15 p.m.-5:20 p.m. Introduction
Robert West, Stanford University, Stanford, California and Esther H. Lips Netherlands Cancer Institute, Amsterdam, The Netherlands

*Lightning Talk selected from proffered abstracts
5:20 p.m.-5:35 p.m.  **Mammary epithelial architecture modulates field cancerization**  
Hendrik Messal, Netherlands Cancer Institute, Amsterdam, The Netherlands

5:35 p.m.-5:50 p.m.  **A single-cell and spatial investigation of tumor and TME for DCIS**  
Runmin Wei, UT MD Anderson Cancer Center, Houston, Texas

5:50 p.m.-6:05 p.m.  Panel Discussion

**6:05 p.m.-7:20 p.m.**  **Session 2: How Can We Optimize Risk Stratification Over Time for DCIS?**  
*Moderator: Jelle Wesseling, Netherlands Cancer Institute, Amsterdam, The Netherlands*

6:05 p.m.-6:20 p.m.  **Artificial intelligence for TIL scoring (AI-TIL)**  
Yinyin Yuan, Institute of Cancer Research, London, United Kingdom

6:20 p.m.-6:35 p.m.  **The DCIS: A biological challenge and clinical dilemma**  
Sudhir Srivastava, National Cancer Institute, Bethesda, Maryland

6:35 p.m.-6:50 p.m.  **Artificial intelligence approaches to DCIS grading and recurrence prediction**  
Jonas Teuwen, Netherlands Cancer Institute, Amsterdam, The Netherlands

6:50 p.m.-7:05 p.m.  **Managing large-scale consortia**  
Jelle Wesseling

7:05 p.m.-7:20 p.m.  Panel Discussion

**SATURDAY, SEPTEMBER 10**

7:00 a.m.–8:00 a.m.  **Breakfast**  
Liberty Ballroom AB

8:00 a.m.–10:00 a.m.  **Plenary Session 4: What is the role of our current surgical treatments? [CME Eligible]**  
Liberty Ballroom CD  
*Session Chair: Alistair Thompson, Dan L. Duncan Comprehensive Cancer Center, Houston, Texas*

8:00 a.m.-8:30 a.m.  **Surgery for DCIS: If, what and when**

*Lightning Talk selected from proffered abstracts*
8:30 a.m.-9:00 a.m.  
**After DCIS surgery, what next? The prevention of future breast events**  
Seema A. Khan, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

9:00 a.m.-9:10 a.m.  
**Lightning talks from submitted abstracts**

- **Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers**  
  Gillian Hirst, University of California San Francisco, San Francisco, California

- **Breast Cancer (BC) risk reduction in young women with Ductal Carcinoma in Situ (DCIS)**  
  Megan Tesch, Dana-Farber Cancer Institute, Boston, Massachusetts

9:10 a.m.-9:40 a.m.  
**Challenges in conducting active surveillance for DCIS**  
Thomas Lynch, Duke Cancer Institute, Durham, North Carolina

9:40 a.m.-10:00 a.m.  
**Discussion**

10:00 a.m.-10:30 a.m.  
**Break**  
Liberty Ballroom Foyer

10:30 a.m.-12:40 p.m.  
**Plenary Session 5: Imaging [CME Eligible]**  
Liberty Ballroom CD  
*Session Chair: Heather Greenwood, University of California San Francisco, San Francisco, California*

10:30 a.m.-11:00 a.m.  
**Imaging tools for DCIS: Past, present and future**  
Constance Lehman, Harvard University/Massachusetts General Hospital, Boston, Massachusetts

11:00 a.m.-11:30 a.m.  
**MR Imaging of active surveillance of DCIS - What we have learned so far**  
Heather Greenwood, University of California San Francisco, San Francisco, California

---

*Lightning Talk selected from proffered abstracts*
11:30 a.m.-11:40 a.m.  Lightning talks from submitted abstracts

Characterizing N-glycan profiles of DCIS progression using tissue imaging MALDI mass spectrometry*
Elizabeth Wallace, Medical University of South Carolina, Charleston, South Carolina

DCIS-associated myoepithelial cells drive tumor progressive inflammation through up-regulation of integrin αvβ6*
Michael Allen, Queen Mary University of London, Barts Cancer Institute, London, United Kingdom

11:40 a.m.-12:10 p.m.  Ductal carcinoma in situ (DCIS) and MRI: Challenges translating MRI depiction of DCIS to improved clinical performance and future opportunities to optimize treatment
Habib Rahbar, University of Washington School of Medicine, Seattle, Washington

12:10 p.m.-12:40 p.m.  Image-based risk assessment
Regina Barzilay, Massachusetts Institute of Technology, Cambridge, Massachusetts

12:40 p.m.-2:30 p.m.  Lunch on own

2:30 p.m.-4:30 p.m.  Plenary Session 6: Controversies in Clinical Care (debate format)
[CME Eligible]
Liberty Ballroom CD
Moderator: Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

DCIS should not be called cancer
2:30 p.m.-2:45 p.m.  Jennifer L. Marti, Weill Cornell Medicine, New York, New York

DCIS or cancer? Why all the confusion?
2:45 p.m.-3:00 p.m.  Steven Narod, Women's College Research Institute, Toronto, Canada

It is time to rethink local therapy for DCIS-enhanced image guided radiation therapy?
3:00 p.m.-3:30 p.m.  Discussion

*Lightning Talk selected from proffered abstracts
3:30 p.m.-3:45 p.m.  For: Nicolas D. Prionas, University of California San Francisco, San Francisco, California

3:45 p.m.-4:00 p.m.  Against: Bruce Mann, Royal Melbourne Hospital, Parkville, Australia

4:00 p.m.-4:30 p.m.  Discussion

4:45 p.m.-7:00 p.m.  POSTER SESSION B / RECEPTION
Liberty Ballroom AB

SUNDAY, SEPTEMBER 11
7:00 a.m.–8:00 a.m.  Breakfast
Liberty Ballroom AB

8:00 a.m.–9:45 a.m.  Plenary Session 7: Molecular Sequencing [CME Eligible]
Liberty Ballroom CD
Session Chair: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts

8:00 a.m.-8:30 a.m.  Molecular subtypes and spatial heterogeneity in DCIS
Therese Sørlie, Oslo University Hospital, Oslo, Norway

8:30 a.m.-9:00 a.m.  Decoding DCIS progression & recurrence with single cell genomics
Nicholas E. Navin, UT MD Anderson Cancer Center, Houston, Texas

9:00 a.m.-9:30 a.m.  Spatial ontologies for predicting invasive progression in ductal carcinoma in situ
R. Michael Angelo, Stanford University, Stanford, California

9:30 a.m.-9:45 a.m.  Discussion

9:45 a.m.–10:15 a.m.  Break
Liberty Ballroom Foyer

10:15 a.m.–12:00 p.m.  Plenary Session 8: Microenvironment [CME Eligible]
Liberty Ballroom CD
Session Chair: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts

10:15 a.m.-10:45 a.m.  What is an invasion permissive/promoting microenvironment? Clues for prevention

*Lightning Talk selected from proffered abstracts
Alexander D. Borowsky, University of California-Davis, Davis, California

10:45 a.m.-11:15 a.m.  Compromised myoepithelial cell differentiation correlates with DCIS to IDC transition
Pepper Schedin, Oregon Health & Science University, Portland, Oregon

11:15 a.m.-11:45 a.m.  DCIS to IDC progression - a key step of immune escape
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts

11:45 a.m.-12:00 p.m.  Discussion

12:15 p.m.-1:00 p.m.  Closing Keynote [CME Eligible]
Liberty Ballroom CD
Session Chair: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts

The hitchhikers guide to the universe of DCIS
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

1:00 p.m.  Closing Remarks
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts